SACUHART VA V.2

SACUHART VA V.2

Published on 12 February 2023
Transcript
00:00
Dear Doctor, Add more life to their years, As Sacuhart reduces hospitalisation and mortality risk Sacuhart Lowers Re-hospitalisation with 21% RRR when switched from ACEi and upto 44% in ADHF vs ACEi Sacuhart Lowers Risk of CV death with upto 20% RRR when switched from ACEi and upto 34% in ADHF vs ACEi
00:33
Dear Doctor, once HF is ascertained with ECHO and NT-ProBNP. Start SACUHART in HFrEF as replacement for ACEi/ARB and in De Novo HFrEF (ACEi/ARB Naive) When the patient is stable in OPD or IPD Doctor start SACUHART 50mg BID or 100mg BID and titrate up at 2-4 weeks gap to maximum tolerated dose of 200 mg BID Doctor, SACUHART to be consumed with or without food
01:09
Doctor your reliance on our quality won’t fail Doctor for Sacuhart, Molar Ratio is 1:1 and is formulated in amorphous anionic form Doctor in SACUHART, graph of Valsartan and Sacubitril clearly shows that Sacuhart is bioequivalent to international standard and its amorphous form matches Co-Crystal form Doctor Sacuhart is self manufactured by Macleods
01:38
Doctor, Promise to secure the failing Hearts Please prescribe in every HFrEF patient, SACUHART and secure the failing heart As they still have more to live